Bipolar disorder affects about 2.8% of U.S. adults and involves episodes of mania or hypomania alternating with depression. Current treatment typically combines mood stabilizers like lithium or valproate, atypical antipsychotics, and sometimes antidepressants. Many people find a regimen that prevents severe episodes, though finding the right combination can take time.
What's actually going on in research
Trials are testing new antipsychotics with fewer metabolic side effects, faster-acting drugs for acute mania and depression, and treatments targeting specific symptoms like mixed episodes or cognitive problems. Researchers are also studying ketamine and psilocybin for treatment-resistant bipolar depression, digital tools for tracking mood patterns, and biomarkers that might predict which medications will work for which patients.
Rapid-acting treatments
Ketamine and related drugs may lift bipolar depression within hours rather than weeks. Trials are testing whether they work safely in bipolar disorder, where antidepressants can trigger mania.
Metabolic-friendly antipsychotics
Newer antipsychotics aim to stabilize mood without the weight gain and diabetes risk of older drugs. Several are in late-stage testing for mania and maintenance treatment.
Digital monitoring
Apps and wearables that track sleep, activity, and mood may catch early warning signs of episodes. Studies are testing whether this real-time data helps people stay stable longer.
What to know before you search
Eligibility usually depends on bipolar type (I or II), current episode (manic, depressive, or mixed), recent medication history, and absence of substance use disorders or certain other conditions.
What types of trials are currently open
- Acute mania trials — Testing medications to calm manic episodes, usually in hospital or closely monitored settings. Most compare a new drug to placebo or an existing antipsychotic.
- Bipolar depression trials — Testing treatments for depressive episodes, including new antipsychotics, ketamine, and combinations. A major challenge is lifting depression without triggering mania.
- Maintenance trials — Testing whether a drug prevents future episodes over months or years. Participants are usually stable when they enroll and stay on the drug long-term.
- Mixed episode trials — Testing drugs for episodes with both manic and depressive symptoms at once, which are harder to treat than pure mania or depression.
- Cognitive trials — Testing treatments for memory, attention, and executive function problems, which persist even when mood is stable.
Recently added Bipolar Disorder trials
Receive a heat-based procedure to reduce knee arthritis pain
This study aims to compare the efficacy of unipolar versus bipolar radiofrequency ablation (RFA) in knee osteoarthritis pain.
Receive a brain implant to treat severe bipolar depression
This study addresses a critical unmet need in the treatment of bipolar disorder by investigating whether Subcallosal Cingulate (SCC) Deep Brain Stimulation (DBS) can safely and effectively treat treatment-resistant bipolar depression without inducing manic switches. The researchers propose to accomplish this by incorporating monitoring of the SCC local field potentials (LFP) for depression tracking and amygdala LFP monitoring for mania prediction while treating Bipolar I patients with SCC DBS Stimulation. This approach could establish a new paradigm for personalized neuromodulation therapy that uses real-time neural monitoring to optimize outcomes while minimizing risks. By incorporating bilateral, dual-site LFP monitoring from both the SCC and amygdala, this research will allow the researchers to assess the therapeutic efficacy of continuous SCC-DBS and develop novel safety biomarkers that could transform the clinical management of DBS therapy in psychiatry. The findings will have immediate implications for clinical practice and will advance the study team's fundamental understanding of the neural circuits underlying mood regulation and dysregulation in bipolar disorder.
Find Bipolar Disorder trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.